Compare Becton Dickinson and Co (BDX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.65. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | VEA | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | — |
52-Week High | $185.39 | $72.39 |
52-Week Low | $135.49 | $56.02 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
VEA trades at $69.76, down 1.73% over the past day, with technical indicators signaling a bearish trend. The ETF offers broad exposure to developed international markets with a low expense ratio of 0.03% and a forward P/E of 17.7x, providing a valuation discount to US equities. Recent news highlights its outperformance versus US benchmarks and strong asset growth under Vanguard's management.
Outlook remains positive for long-term diversification given its cost efficiency and geographic reach, though near-term risks include central bank rate hikes and political uncertainty in key markets like the UK. The bearish technical setup suggests potential for further consolidation before resuming upward momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
